Showing results (311-320 of 323) with videos related to
Sort By:
Pageof 33
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 7, 2019
Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastomaNalee Kim, Jee Suk Chang, Chan Woo Wee, et al.Cancer Medicine|December 10, 2021
The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter studyJwa Hoon Kim, Seyoung Seo, Jee Hyun Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2022
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung CancerSehhoon Park, Chan-Young Ock, Hyojin Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.Nature|May 6, 2021
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanomaIvana Yen, Frances Shanahan, Jeeyun Lee, et al.Brain Tumor Research and Treatment|November 6, 2019
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01Young Zoon Kim, Chae Yong Kim, Jaejoon Lim, et al.Brain Tumor Research and Treatment|November 6, 2019
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01Young Zoon Kim, Chae Yong Kim, Chan Woo Wee, et al.The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, et al.Pageof 33